The efficiency of antiviral therapy in patients with chronic hepatitis C infected with hepatitis C virus recombinants

Abstract

The review gives the data available in the literature in the efficiency of treatment in patients with chronic hepatitis C infected with hepatitis C virus.(HCV) recombinants, by applying various antiviral therapy regimens. The low efficiency of treatment with- pegylated interferons (PEG IFN) + ribavirin (RIB) and sofosburin (SOF) +RIB in this patient group (a sustained virologic response was achieved in 22 and 30.7%, respectively) compared with the efficiency of treatment (87-97 and 83-97%, respectively) inpatients infected with HCV genotype 2 does not allow the 2015 EASL HCV genotype 2 treatment regimens to be used in. such patients. In this connection, subtyping genotype 2 isolates by NS5B sequencing should be introduced into clinical laboratory practice to successfully detect recombinant HCVs and to enhance the efficiency of antiviral therapy.

Improvement of the Effectiveness of Antiviral Treatment of Patients with Chronic Hepatitis C and Concomitant Diabetes Mellitus Type II using Alpha-Lipoic Acid and Lactulose

“…Thus, we consider the determination of the prevalence of immune response type with the production of certain cytokines to be the basis not only for more accurate understanding of the pathological process and CHC prognosis but also for the effectiveness of treatment [17,19]. Currently, the need to develop "maintenance" therapy when conducting specific AVT which would provide sustained viral response through the correction of the main pathogenetic changes (namely, cytokine system) is an important therapeutic issue regarding CHC for many foreign researchers.…”